What is the Share Price of Glaxosmithkline Pharmaceuticals Ltd?

Glaxosmithkline Pharmaceuticals Ltd share price is ₹1,871.20 As on 20 April, 2024|18:19

Home
>
Share Price
>
Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd

Q: What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd?

The Market Cap of Glaxosmithkline Pharmaceuticals Ltd is ₹31,682 As on 20 April, 2024|18:19

Q: What is PE Ratio of Glaxosmithkline Pharmaceuticals Ltd?

The P/E ratio of Glaxosmithkline Pharmaceuticals Ltd is 49.4 As on 20 April, 2024|18:19

Q: What is PB Ratio of Glaxosmithkline Pharmaceuticals Ltd?

The PB ratio of Glaxosmithkline Pharmaceuticals Ltd is 20.59 As on 20 April, 2024|18:19

₹ 1,871.20 -16.95 (-0.90%)
Updated on 19-04-2024 4:55 PM

Stock Rating

Pros 4

Cons 3

Price Performance

Day's Low
₹1,854

Day's High
₹1,878.20

₹ 1,871.20

52-w low
₹1,227

52-w high
₹2,524

1,871.20

Day's open
₹1,878.15
Previous close
₹1,888.15
VWAP
₹1,867.89
Lower price band
₹1,510.55
Upper price band
₹2,265.75

Today's Market Action

The last traded share price of Glaxosmithkline Pharmaceuticals Ltd was 1,871.20 down by -0.90% on the NSE. Its last traded stock price on BSE was 1,868.85 down by -1.08%. The total volume of shares on NSE and BSE combined was 49,219 shares. Its total combined turnover was Rs 9.19 crores.

Medium and Long Term Market Action

Glaxosmithkline Pharmaceuticals Ltd hit a 52-week high of 2,524 on 06-02-2024 and a 52-week low of 1,227 on 03-05-2023. The stock price of Glaxosmithkline Pharmaceuticals Ltd is down by -6% over the last one month. It is up by 50.42% over the last one year. Don't forget to check the full stock price history in the table below.

Fundamentals

Market Cap (Cr): 31682
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About

Data not available.

FAQ's

What is Share Price of Glaxosmithkline Pharmaceuticals Ltd?

What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd?

What is PE Ratio of Glaxosmithkline Pharmaceuticals Ltd?

What is PB Ratio of Glaxosmithkline Pharmaceuticals Ltd?

What is the CAGR of Glaxosmithkline Pharmaceuticals Ltd?

How to Buy Glaxosmithkline Pharmaceuticals Ltd Share?

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

Pros

Above Average Sustainable RoE
The company generates a sustainable return on equity greater than the expected cost of capital which implies that the underlying business can create and compound value over a period time due to it's ability to generate above average return on capital.
High Pricing Power
The business enjoys a relatively high pricing power and is able to withstand competitive pressure which works as a great moat for equity shareholders of the company.
Asset Light Business
The company operates a great asset light business with a high Asset turnover ratio of 9.63. A high asset turnover ratio is a great driver of RoE and can improve shareholder returns. A relatively higher asset turnover ratio also will result in lower dilution as the business grows its revenues as earnings.
Zero Debt
The company has almost nil to negligible debt to equity ratio of 0.01. Considering the fact that the business is debt free, equity shareholders shall carry lower risk of holding the stock.

Cons

Momentum Strength
The stock is currently exhibiting weak momentum, & is showing weak relative strength.
Highly Cyclical Industry
The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
Poor Capital Allocation
The company has disproportionately high amount of assets locked up in working capital, cash and cash equivalents, loans and advances, etc to the extent of 73.76 % of total assets. This reflects poorly on the capital allocation strategy of the management which negatively impacts shareholder returns.

Valuation Analysis

Margin of safety
(20/04/2024)

Margin of Safety Index: High

87.50%

87.50% People are bullish about Glaxosmithkline Pharmaceuticals Ltd

12.50%

12.50 % People are bearish about Glaxosmithkline Pharmaceuticals Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %